Malignant Peripheral Nerve Sheath Tumor Clinical Trials

2 recruiting

Malignant Peripheral Nerve Sheath Tumor Trials at a Glance

10 actively recruiting trials for malignant peripheral nerve sheath tumor are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Boston, New York, and St Louis. Lead sponsors running malignant peripheral nerve sheath tumor studies include Memorial Sloan Kettering Cancer Center, HRYZ Biotech Co., and Fudan University.

Browse malignant peripheral nerve sheath tumor trials by phase

Treatments under study

About Malignant Peripheral Nerve Sheath Tumor Clinical Trials

Looking for clinical trials for Malignant Peripheral Nerve Sheath Tumor? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Peripheral Nerve Sheath Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Peripheral Nerve Sheath Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Malignant Peripheral Nerve Sheath Tumors
Washington University School of Medicine1,050 enrolled13 locationsNCT03141021
Recruiting
Phase 1Phase 2

SPEARHEAD-3 Pediatric Study

OsteosarcomaSynovial SarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)+1 more
USWM CT, LLC20 enrolled10 locationsNCT05642455
Recruiting
Phase 2

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT04872543
Recruiting
Early Phase 1

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

Primary Malignant Peripheral Nerve Sheath Tumors
University of Minnesota8 enrolled1 locationNCT06693284
Recruiting

Neurofibromatosis Type 1 Tumor Early Detection Study

Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Neurofibromatosis 1+4 more
David Miller1,000 enrolled1 locationNCT06515860
Recruiting
Phase 2

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

AngiosarcomaLeiomyosarcomaDesmoplastic Small Round Cell Tumor+4 more
Fudan University45 enrolled1 locationNCT06849986
Recruiting
Phase 2

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

AngiosarcomaLeiomyosarcomaSynovial Sarcoma+8 more
HRYZ Biotech Co.148 enrolled1 locationNCT06277154